NCT00416429View on ClinicalTrials.gov

Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

456

Participants

Timeline

Start Date

Not specified

Study Completion Date

February 28, 2005

Conditions

Kidney Cancer

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

recombinant interferon alpha-2a

DRUG

medroxyprogesterone

All Listed Sponsors

lead

Centre Leon Berard

OTHER

NCT00416429 - Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter